Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alcobra Ltd (NASDAQ:ADHD)

0.9849
Delayed Data
As of Jan 19
 -0.0451 / -4.38%
Today’s Change
0.83
Today|||52-Week Range
5.75
-53.10%
Year-to-Date
Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug
Jan 18 / Zacks.com - Paid Partner Content
Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Tops Q4 Estimates
Jan 17 / Benzinga - Paid Partner Content
Alcobra Shares Plummet as ADHD Drug Fails
Jan 17 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close1.03
Today’s open1.02
Day’s range0.97 - 1.03
Volume1,527,000
Average volume (3 months)561,984
Market cap$28.4M
Dividend yield--
Data as of 01/19/2017

Growth & Valuation

Earnings growth (last year)+62.50%
Earnings growth (this year)-4.13%
Earnings growth (next 5 years)--
Revenue growth (last year)--
P/E ratio--
Price/Sales--
Price/Book0.41

Competitors

 Today’s
change
Today’s
% change
NVGNNovogen Ltd+0.01+0.61%
IMNPImmune Pharmaceutica...-0.01-6.13%
PTXPernix Therapeutics ...-0.24-7.87%
ANTHAnthera Pharmaceutic...-0.04-5.69%
Data as of 01/19/2017

Financials

Next reporting dateFebruary 16, 2017
EPS forecast (this quarter)-$0.26
Annual revenue (last year)$0.00
Annual profit (last year)-$19.4M
Net profit margin--

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Yaron Daniely
Chief Operating Officer &
Chief Financial Officer
Tomer Berkovitz
Corporate headquarters
Tel Aviv, Tel Aviv

Forecasts


Search for Jobs